Leonard S. Schleifer Salary and Compensation - REGENERON PHARMACEUTICALS, INC. CEO Pay 2024

In fiscal year 2024, Leonard S. Schleifer, M.D., Ph.D. Board co-Chair, President and Chief Executive Officer of REGENERON PHARMACEUTICALS, INC. (REGN), received total compensation of $6.8 million.

Leonard S. Schleifer's compensation breakdown includes: base salary of $1.9 million, non-equity incentive compensation of $3.5 million, and other compensation of $1.4 million.

Compared to fiscal year 2023, Leonard S. Schleifer's total compensation decreased 17% from $8.2 million to $6.8 million.

REGENERON PHARMACEUTICALS, INC. (REGN) Executive Pay 2024

REGENERON PHARMACEUTICALS, INC.'s top 6 named executive officers received combined total compensation of $37.2 million in fiscal year 2024.

The named executive officers disclosed in REGENERON PHARMACEUTICALS, INC.'s 2024 proxy statement are:Leonard S. Schleifer (M.D., Ph.D. Board co-Chair, President and Chief Executive Officer) with total compensation of $6.8 million, Daniel P. Van Plew (Executive Vice President and General Manager Industrial Operations and Product Supply) with total compensation of $8.7 million, Andrew J. Murphy (Ph.D. Executive Vice President, Research) with total compensation of $8.4 million, George D. Yancopoulos (M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer) with total compensation of $6.8 million, Christopher Fenimore (Executive Vice President Finance and Chief Financial Officer) with total compensation of $6.3 million, and Robert E. Landry (retired) (Retired ) Former Executive Vice President Finance and Chief Financial Officer) with total compensation of $282K.